SECONDARY METABOLITES OF ANTAGONISTIC BACTERIAL STRAIN Cytobacillus firmus TCP1 EXERT ANTIBACTERIAL AND ANTICANCER ACTIVITY AGAINST LUNG CANCER A549 CELLS

Marine bacteria are abundant producers of many different kinds of bioactive substances. In this study, we isolated the antagonistic marine bacterial strain Cytobacillus firmus TCP1 from soil samples collected from the shoreline and evaluated the antibacterial and anticancer effects of its crude secondary metabolites. The potent antagonistic bacterial isolate C. firmus was identified using 16S rRNA sequencing analysis. The secondary metabolites from strain C. firmus were extracted by centrifugation with ethanol, and the agar well diffusion method was used to evaluate them for antibacterial activity against respiratory tract bacterial pathogens. This study demonstrated that the metabolic extract of the TCP1 effectively inhibited the growth of respiratory tract bacterial pathogens. Moreover, it established concentration-dependent cytotoxicity on A549 lung cancer cells. The administration of metabolic extract of the TCP1 showed an effective inhibitory effect on colony formation of A549 cells, increased lipid peroxidation, and decreased the antioxidant activity in A549 cells. The results showed that the metabolic extract of the TCP1 showed effective antibacterial and anticancer activity. Therefore, upon additional clinical testing, the secondary metabolites of strain C. firmus TCP1 may be exploited to create potent antibiotics and anticancer drugs for lung cancer.